Global Dosimetry Solutions, Inc., Promotes Louis Biacchi as VP Worldwide Sales

Costa Mesa, Calif., July 26, 2004 - Global Dosimetry Solutions, Inc. (GDS) a leading provider of dosimetry services (analytical determination of exposure to ionizing radiation) has announced the promotion of Louis Biacchi to Vice President of Worldwide Sales. Formerly the Director of Worldwide sales for large accounts, Biacchi's new role will include responsibility for the management and sales of all GDS accounts including small office medical practices, and industrial applications.

Lou's career with GDS spans over 10 years. He began his career as Program Manager of the TLD product line, before transitioning to sales in 1997. In 1998, he became North American Sales Manager, and in 1999 he was promoted to Director. Lou graduated from Bloomsburg University with a BS in Health Physics.

"Lou is a dynamic leader with a proven track record of accomplishments," said Thomas Logan, CEO of Global Dosimetry. "His success is directly attributable to an uncompromising customer focus, coupled with a tremendous knowledge base."

"I look forward to taking on the new challenges and responsibilities of this position and further contributing to the success of GDS," said Biacchi, "My goal is to continually improve customer satisfaction, while we enhance what is already the finest service available in the dosimetry marketplace."

Global Dosimetry Solutions, based in Irvine, California, is one of the world's largest providers of radiation dosimetry services. GDS offers a full range of services for measuring ionizing radiation primarily through film, thermoluminescent and track etch technologies. Since early 1970, the company has continually provided state-of-the-art personal radiation monitoring services to hospitals, medical and dental offices, university and national laboratories, nuclear power plants and other industries. GDS provides services to more than 500,000 people globally. Global Dosimetry Solutions is majority owned by American Capital Strategies, Ltd. (NASDAQ: ACAS), a $3.5 billion investment fund headquartered in Bethesda, Maryland. For more information, please visit: www.dosimetry.com.